- Evusheld is a combination of two monoclonal antibodies specifically designed to help your body fight COVID-19.
- Antibodies are proteins your immune system makes that help you fight infections. Monoclonal antibodies are antibodies that are made in a lab instead of being made by your immune system.
- Current CDC guidelines recommend that Euvsheld be administered to people who are moderately or severely immunocompromised every 6 months to supplement vaccine protection.
- Most vasculitis patients should receive Evusheld. Contact your healthcare provider for more information.
- It is strongly recommended that vasculitis patients on high level immunosuppressants such as rituximab or cyclophosphamide receive Evusheld.
Here are some resources from the FDA to help answer those question.
- FDA releases important information about risk of COVID-19 due to certain variants not neutralized by Evusheld
- FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants
- On July 21, 2022 Astrazeneca, the makers of evusheld, released this statement about the effectiveness of evusheld against Omicron variants BA.5, BA.4 and BA.2.
- Evusheld may be given at least 2 weeks after any COVID-19 vaccine.
- After this interval, Evusheld may be initiated at any time between primary series and booster doses.
- COVID-19 vaccines may be administered at any time after Evusheld administration.
- Use of monoclonal antibodies is not a substitute for COVID-19 vaccination.
We were not able to find any official position statements on this question. Consult with your healthcare provider to determine when you can receive Evusheld after receiving monoclonal antibodies.
Evusheld is an FDA Emergency Use Authorized (EUA) medication that can be given as a pre-exposure prophylactic treatment to patients who meet certain criteria.
Let’s break that down.
Emergency Use Authorization
The FDA has approved this medication for use before it has gone through the full range of testing normally required for FDA approval because:
- A healthcare emergency has been declared.
- The treatment has shown evidence of effectiveness.
- In the FDA’s analysis, the benefits of treatment outweigh the risks.
- There is currently no available alternative treatment that is FDA approved.
Medication given prior to exposure to a disease-causing agent to help prevent the spread of the disease.
Evusheld is a combination of two antibodies designed to help your immune system fight COVID-19.
A vaccine encourages your immune system to produce antibodies. When you are taking medications which suppress your immune system and receive a vaccine, your body may not produce very many antibodies. This means when your immune system goes to battle against the disease it is working with a much smaller army.
Evusheld antibodies are white blood cells that have been cloned in a lab that are ready to fight COVID-19. Evusheld may help boost the size of your disease fighting army.